Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for American Well Corporation (Amwell) (NYSE: AMWL) brings together the company’s official regulatory disclosures, as filed with the U.S. Securities and Exchange Commission. These documents provide detailed information on Amwell’s financial reporting, material agreements and other significant corporate events related to its digital care and technology-enabled healthcare platform.
Among the key filings are Form 8‑K current reports, which Amwell uses to announce material events. Recent 8‑K filings include disclosures of quarterly financial results, with earnings reports furnished as exhibits and details on investor conference calls and webcasts. Other 8‑K filings describe material definitive agreements, such as amendments and statements of work with Elevance Health under which Amwell operates the LiveHealth Online white‑label digital care platform and receives annual subscription fees and related service fees.
Filings also outline amendments to provider agreements involving Online Care Group, P.C., Amwell’s clinical partner, which maintains a 50‑state network of clinical professionals delivering digital care consultations via the LiveHealth Online platform. These documents specify contract terms, renewal provisions and termination rights, offering insight into how Amwell structures long‑term partnerships that support its technology-enabled care services.
On Stock Titan, investors can use AI-powered tools to read and interpret Amwell’s SEC filings more efficiently. AI summaries highlight the main points of lengthy documents, explain the implications of material agreements and clarify the context of earnings-related disclosures. Real-time updates from EDGAR ensure that new 8‑K filings and other reports appear promptly, while structured access to exhibits helps users locate information on subscription arrangements, provider networks and other aspects of Amwell’s business.
For anyone analyzing AMWL, this page serves as a focused entry point into Amwell’s regulatory history, combining raw SEC documents with AI-generated explanations that make complex legal and financial language easier to understand.
American Well Corporation disclosed that it has extended its long-standing partnership with Elevance Health, Inc. for digital care services. On December 24 and 25, 2025, the company amended its Master Services Agreement and entered into a new Healthy Impact Statement of Work, effective January 1, 2026, to continue operating the white‑labelled LiveHealth Online® digital care platform. Under these agreements, Elevance Health pays annual subscription fees and can engage American Well for additional professional, development, innovation, and engagement marketing services.
Both the Master Services Agreement and the Healthy Impact Statement of Work now run for 3 years from January 1, 2026 through January 1, 2029, with automatic one‑year renewals unless terminated. Elevance Health has various termination rights, including for convenience with 365 days’ notice. American Well’s clinical partner, Online Care Group, PC, also extended related provider agreements for the same 3‑year term, ensuring continued prioritized access to a 50‑state network of clinicians who deliver digital care consultations to Elevance Health members via LiveHealth Online.
American Well Corporation reported a planned sale of restricted stock under Rule 144. The notice covers the proposed sale of 6,243 shares of Class A common stock through Morgan Stanley on the NYSE, with an aggregate market value of $30,284.79. The filing states that 14,723,951 shares of this class were outstanding and lists an approximate sale date of 01/02/2026.
The shares to be sold were acquired through the vesting of a restricted stock unit grant from American Well Corporation on 01/01/2026, when 11,831 shares vested and were treated as payment by vesting. The form also notes that the seller represents they are not aware of undisclosed material adverse information about the company’s current or prospective operations.
American Well Corporation insider Phyllis Gotlib has filed a notice of proposed sale of Class A Common Stock under Rule 144. The filing indicates an intent to sell 3,707 shares through broker Morgan Stanley on or about 01/02/2026, with an aggregate market value of $17,982.66, on the NYSE.
The shares to be sold come from a vesting event of restricted stock units. On 01/01/2026, 7,031 Class A shares were acquired through the vesting of a restricted stock unit grant from American Well Corporation, with payment also described as vesting of that grant. The filing also lists prior sales by Phyllis Gotlib over the past three months: 3,574 Class A shares sold on 12/01/2025 for gross proceeds of $14,501, and 4,959 Class A shares sold on 10/01/2025 for gross proceeds of $30,282.
American Well Corp director reports a small stock sale. A reporting person serving as a director of American Well Corp sold Class A Common Stock on 12/18/2025, in two market transactions: 600 shares at $4.71 per share and 12 shares at $4.75 per share, both held indirectly through her husband. After these sales, the indirect holdings through her husband were reduced to zero shares, while she continued to beneficially own 39,132 shares of Class A Common Stock directly.
American Well Corp reported an insider transaction by its President, International. On December 1, 2025, the reporting person sold 3,574 shares of Class A common stock at a price of $4.0573 per share. The filing explains that these sales were made solely to pay taxes arising from the vesting and settlement of restricted stock units on the same date through an automatic “sell to cover” transaction, rather than a discretionary trade.
After this transaction, the reporting person beneficially owns 123,577 Class A shares directly and 114,250 Class A shares indirectly through her husband. This reflects ongoing equity ownership in American Well while handling the tax impact of stock-based compensation.
American Well Corporation insider Phyllis Gotlib has filed a notice to sell 3,574 shares of Class A common stock through Morgan Stanley on the NYSE, with an aggregate market value of 14,501. The company reports 14,723,951 Class A shares outstanding, so this is a small transaction relative to the total.
The shares to be sold are tied to a restricted stock unit grant, with 6,786 Class A shares vesting on 12/01/2025 and paid via that vesting. Over the prior three months, Gotlib sold 4,781 and 4,959 Class A shares on 09/02/2025 and 10/01/2025, generating gross proceeds of 32,422.35 and 30,281.64. By signing the notice, the seller represents that she is not aware of any undisclosed material adverse information about American Well’s operations.
Caledonia (Private) Investments Pty Limited and Caledonia US, LP filed Amendment No. 4 to Schedule 13G reporting their beneficial ownership in American Well Corp (AMWL).
The filing lists 640,000 shares of Class A common stock with 4.35% of the class, all with shared voting and dispositive power and no sole power. Item 5 indicates “Ownership of 5 percent or less of a class.” The date of the event requiring the filing is 09/30/2025, and the certification states the securities are held in the ordinary course and not to change or influence control.
American Well (AMWL) reported third‑quarter results for the period ended September 30, 2025. Revenue was $56.3 million, down from $61.0 million a year ago, as visit volumes declined while higher‑margin platform subscriptions grew. Loss from operations narrowed to $29.3 million from $47.4 million, reflecting lower costs across R&D, sales and marketing, and cost of revenue.
Platform subscription revenue rose to $30.9 million from $26.2 million, while visit revenue fell to $21.2 million from $27.5 million. Net loss attributable to the company improved to $32.4 million from $43.5 million; basic and diluted net loss per share was $2.00 versus $2.87. Cash, cash equivalents and restricted cash were $201.7 million as of September 30, 2025, compared with $245.4 million a year earlier. Operating cash use for the nine months was $48.6 million, an improvement from $113.9 million.
Year‑to‑date, the company recognized an $8.7 million gain from the January divestiture of its telepsychiatry APC Business. AMWL and Cleveland Clinic agreed to liquidate their CCAW joint venture, with remaining transition activities running through March 31, 2026. Deferred revenue ended at $32.0 million, down from $56.0 million as of December 31, 2024.
American Well Corporation (Amwell) reported that it announced financial results for the fiscal quarter ended September 30, 2025. The company furnished its Earnings Report as Exhibit 99.1.
Amwell will host a conference call to discuss results today at 5 p.m. ET, accessible via live webcast at the provided link. A replay will be available for approximately 90 days at investors.amwell.com. The furnished materials are not deemed “filed” under Section 18 of the Exchange Act.
Paul McNeice, Chief Accounting Officer of American Well Corp (AMWL), reported a sale of 332 shares of Class A common stock on 10/01/2025 at a price of $6.1064 per share. The filing states the sale was an automatic sell-to-cover to satisfy the tax liability from the vesting and settlement of restricted stock units that occurred the same day. After the transaction, the reporting person beneficially owned 3,560 shares. The Form 4 was signed on behalf of Mr. McNeice by an attorney-in-fact on 10/03/2025.